Sacubitril/Valsartan Improves Left Ventricular Ejection Fraction and Reverses Cardiac Remodeling in Taiwanese Patients with Heart Failure and Reduced Ejection Fraction

BACKGROUND: The angiotensin receptor-neprilysin inhibitor sacubitril/valsartan is known to improve outcomes of cardiac death and hospitalization due to heart failure in patients with heart failure and reduced ejection fraction (HFrEF). However, data on improvements in ejection fraction after using s...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:Acta Cardiol Sin
Autori principali: Liu, Li-Wei, Wu, Po-Ching, Chiu, Mei-Ya, Tu, Pei-Fen, Fang, Ching-Chang
Natura: Artigo
Lingua:Inglês
Pubblicazione: Taiwan Society of Cardiology 2020
Soggetti:
Original Article
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC7062818/
https://ncbi.nlm.nih.gov/pubmed/32201463
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.6515/ACS.202003_36(2).20190812A
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi